- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
An anonymous UK health professional complained Avamys’ generic name was unreadable in a Pulse website banner. PMCPA found breaches of Clauses 4.3…
PMCPA ruled Vifor’s Ferinject site landing page promoted a POM to the public (Clause 26.1) and an HCP claim that Ferinject was…
Employee alleged Jinarc EU risk minimisation materials omitted pregnancy/dehydration info and that Otsuka lacked urgency on patient safety. Panel and Appeal Board…
MSD promoted a diabetes/CVD meeting via a targeted LinkedIn sponsored post. A complainant said a patient saw it and couldn’t register. Panel…
Anonymous complaint about Boehringer Ingelheim’s Twitter/Facebook activity advertising a webinar. Panel found the Twitter ad and registration page were non-promotional and gated…
Novartis’ Beovu journal ad claimed it ‘outperformed aflibercept’ on retinal fluid resolution. PMCPA ruled the headline misleading: it overplayed a secondary/exploratory endpoint…
Anonymous GP alleged a Pfizer rep disparaged Xarelto and claimed Eliquis’ superior safety should be used to address mortality in primary care.…
A subcontracted agency posted Oxlumo brand/indication details on LinkedIn. PMCPA ruled promotion of a POM to the public (Clause 26.1 breach). No…
PMCPA found breaches for GSK respiratory materials: meeting invitations omitted non-proprietary names/black triangles/AE statement, one invite implied Trelegy was licensed for asthma,…
A senior UK employee ‘liked’ a global LinkedIn post naming tildrakizumab/Ilumetri and 5-year efficacy/safety. Panel found this proactively disseminated promotion (incl to…
Anonymous employee alleged pressure to obtain HCP email consent (e-permissions). PMCPA found bonus-scheme slides were briefing material and should have been certified…
A certified Gazyvaro nurse leavepiece listed Cycle 1 Day 1 dose as 1000mg instead of 100mg. PMCPA ruled it inaccurate/misleading, not high…
PMCPA found Pfizer’s 2 Dec 2020 COVID-19 vaccine press release breached Clause 7.2 and 9.1 for presenting relative risk reduction without sufficient…
Complaint about a third-party contractor’s LinkedIn post linking to Novo Nordisk’s R&D pipeline page. Panel found the post in scope of the…
A health professional complained about GSK’s pipeline and investor webpages. Pipeline page was ruled non-promotional, but investor page wording implied promotional claims…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.